Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “NEURAMINIDASE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 361 records · Page 20Linked to original sources
PubMed1990

Human neuraminidase is a 60 kDa-processing product of prosaposin.

Human neuraminidase was purified from placenta as part of a large molecular weight complex with lysosomal beta-galactosidase and carboxypeptidase. Passage of this purified complex through a sialic acid-affinity column (fetuin-agarose) retained a minor 60 kDa protein which was eluted with 100 mM N-acetylneuraminic acid. This 60 kDa protein is recognized in Western blots of the purified complex by an anti-prosaposin antibody which at the same time was able to inhibit neuraminidase activity in the preparation. Furthermore, probing of cultured skin fibroblasts of patients affected with neuraminidase deficiency using the antiprosaposin antibody revealed an abnormal 57 kDa protein. These results indicate that the 60 kDa protein is derived from prosaposin and has the characteristics of a neuraminidase.

Antibodies↗
PubMed1983

Histochemical localization of neuraminidase in the CNS of mice and fish by means of 5-brom-3-indolyl-alpha-ketoside of 5-N-acetyl-D-neuraminic acid (BI-NeuAc).

The applicability of the 5-brom-3-indolyl-alpha-ketoside of N-acetyl-D-neuraminic acid (BI-NeuAc) as substrate for the histochemical indication of neuraminidase (GOSSRAU et al. 1977) was examined in frozen sections of brain, small intestine and kidney from suckling and adult mice and respectively from a cichlid fish (Sarotherodon mosambicus) with and without formaldehyde fixation. Following biochemical investigations using tritiated gangliosides as substrate a decrease in the activity of neuraminidase took place from about 50 to 80% after tissue fixation with formaldehyde. Nevertheless significant histochemical reactions were found only in fixed tissue sections. The specificity of this reaction was shown by means of inhibitions tests using 2,3-dehydro-2-desoxy-N-acetyl-neuraminic acid according to KUMAR et al. (1981). In contrast to distinct staining of neuraminidase activity in the small intestine and kidney, only faint reactions occurred in brain sections. From this it is concluded that the application of the new synthetic substrate for quantitative staining of neuraminidase seems to be not very suitable for the CNS.

Animals↗
PubMed1987

Adhesion of Erysipelothrix rhusiopathiae to cultured rat aortic endothelial cells. Role of bacterial neuraminidase in the induction of arteritis.

The adhesion of Erysipelothrix rhusiopathiae (E. rhusiopathiae) to the cultured confluent monolayer of rat aortic endothelial cells (EC) and the role of neuraminidase in the interaction between EC and E. rhusiopathiae were examined. One EC line was obtained by collagenase treatment of rat aorta. The EC showed a typical cobblestone appearance and possessed the factor VIII related antigen. When cultured more than two weeks after reaching confluence, the EC formed a vascular plexus-like appearance. E. rhusiopathiae began to adhere to EC within 2 minutes after the beginning of culture and adhered at a constant rate for 20 minutes. The adhesion of bacteria to EC was closely related to the release of sialic acid from the EC. Significantly more bacteria adhered to neuraminidase treated EC, and bacterial adhesion was inhibited dose-dependently by N-acetylneuraminic-lactose, which is the substrate of bacterial neuraminidase. It is concluded that bacterial neuraminidase plays an essential role in initiating the interaction between EC and E. rhusiopathiae, which would contribute to the genesis of arteritis.

Animals↗
PubMed2003

Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents.

We recently reported the first benzoic acid, 1-[4-carboxy-2-(3-pentylamino)phenyl]-5,5-bis(hydroxymethyl)pyrrolidin-2-one (8), that is a potent inhibitor of avian influenza A neuraminidase (N9) and, unlike other reported potent neuraminidase inhibitors, does not contain a basic aliphatic amine or guanidine nor a simple N-acetyl grouping. However, 8 was a poor inhibitor of influenza B neuraminidase. In the present study we further evaluated 8 as an inhibitor of human influenza A NA isolates, and it was effective against N2NA but found to be 160-fold less active against N1NA. We also synthesized analogues of 8 involving moderate modifications of essential substituents on the pyrrolidinone ring. Specifically, the aminomethyl (9), hydroxyethyl (10), and aminoethyl (11) analogues were prepared. Only the most conservative change (compound 9) resulted in continued effective inhibition of influenza A, in addition to a noteworthy increase in the activity of 9 for N1NA. The effectiveness of 9 against influenza B neuraminidase was furthermore improved 10-fold relative to 8, but this activity remained 50-fold poorer than for type A NA.

Benzoates↗
PubMed1999

Purification and immunocytochemical localization of neuraminidase from Tritrichomonas foetus.

Lysis of Tritrichomonas foetus with a solution of the non-ionic detergent Triton X-114 at 0 degree C, followed by low-speed centrifugation, resulted in a detergent-insoluble pellet and a detergent-soluble supernatant. The supernatant was further fractionated by phase separation at 30 degrees C into a detergent-rich phase and an aqueous phase. Neuraminidase activity was mostly located in the detergent-insoluble pellet. When the parasites were incubated with bacterial phosphatidylinositol phospholipase C (PI-PLC) prior to detergent solubilization and phase separation neuraminidase activity was predominantly recovered in aqueous phase, rather than in the pellet and detergent phase. The molecular mass determined by gel permeation in high performance liquid chromatography (HPLC) and SDS-PAGE was 80,000 Da. Indirect immunofluorescence microscopy using polyclonal antibodies raised in rabbits against the purified neuraminidase, indicated that the enzyme is exposed on the cell surface. Previous treatment of the cells with PI-PLC significantly reduced antibody binding. Incubation of cryo-sections with the antibodies followed by detection using gold-labelled anti-rabbit IgG confirmed the presence of neuraminidase in the plasma membrane enclosing the cell body and flagella and in the membrane of vesicles preferentially located at the peripheral region of the protozoan.

Animals↗
PubMed1997

Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.

A series of 94 benzoic acid derivatives was synthesized and tested for its ability to inhibit influenza neuraminidase. The enzyme-inhibitor complex structure was determined by X-ray crystallographic analysis for compounds which inhibited the enzyme. The most potent compound tested in vitro, 5 (4-acetylamino)-3-guanidinobenzoic acid), had an IC50 = 2.5 x 10(-6) M against N9 neuraminidase. Compound 5 was oriented in the active site of the neuraminidase in a manner that was not predicted from the reported active site binding of GANA (4) with neuraminidase. In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally.

Animals↗
PubMed2006

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.

The worldwide spread of H5N1 avian influenza has raised concerns that this virus might acquire the ability to pass readily among humans and cause a pandemic. Two anti-influenza drugs currently being used to treat infected patients are oseltamivir (Tamiflu) and zanamivir (Relenza), both of which target the neuraminidase enzyme of the virus. Reports of the emergence of drug resistance make the development of new anti-influenza molecules a priority. Neuraminidases from influenza type A viruses form two genetically distinct groups: group-1 contains the N1 neuraminidase of the H5N1 avian virus and group-2 contains the N2 and N9 enzymes used for the structure-based design of current drugs. Here we show by X-ray crystallography that these two groups are structurally distinct. Group-1 neuraminidases contain a cavity adjacent to their active sites that closes on ligand binding. Our analysis suggests that it may be possible to exploit the size and location of the group-1 cavity to develop new anti-influenza drugs.

Acetamides↗
PubMed1987

Cellular localization and substrate specificity of isoelectric forms of human liver neuraminidase activity.

The four major isoelectric forms of human liver neuraminidase (with pI values between 3.4 and 4.8) have been isolated by preparative isoelectric focusing and characterized with regard to their substrate specificity using glycoprotein, glycopeptide, oligosaccharide and ganglioside natural substrates. All forms exhibited a rather broad linkage specificity and were capable of hydrolyzing sialic acid glycosidically linked alpha 2-3, alpha 2-6 and alpha 2-8, although differential rates of hydrolysis of the substrates were found for each form. The most acidic form 1 (pI 3.4) was most active on sialyl-lactose, whereas form 2 (pI 3.9) and 3 (pI 4.4) were most active on the more hydrophobic ganglioside substrates. Form 4 (pI 4.8) was most active on the low-Mr hydrophilic substrates (fetuin glycopeptide, sialyl-lactose). Each form was less active on the glycoprotein fetuin than on a glycopeptide derived from fetuin. Organelle-enriched fractions were prepared from fresh human liver tissue and neuraminidase activity on 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid was recovered in plasma membrane, microsomal, lysosomal and cytosolic preparations. Isoelectric focusing of the neuraminidase activity recovered in each of these preparations resulted in significantly different isoelectric profiles (number, relative amounts and pI values of forms) for each preparation. The differential substrate specificity of the isoelectric forms and the different isoelectric focusing profiles of neuraminidase activity recovered in subcellular-enriched fractions suggest that specific isoelectric forms with broad but defined substrate specificity are enriched at separate sites within the cell.

Humans↗
PubMed1990

Structure of the lysosomal neuraminidase-beta-galactosidase-carboxypeptidase multienzymic complex.

Lysosomal neuraminidase (sialidase; EC 3.2.1.18) and beta-galactosidase (EC 3.2.1.23), together with a carboxypeptidase, the so-called 'protective protein', were co-purified from the human placenta by affinity chromatography on a concanavalin A-Sepharose column followed by a thiogalactoside-agarose affinity column for beta-galactosidase. Analysis of the purified material by gel-filtration h.p.l.c. revealed three distinct molecular forms, all with high beta-galactosidase specific activity, but only the largest one expressed neuraminidase activity. Rechromatography of each individual species separately indicated that all three are in fact part of an equilibrium system (the neuraminidase-beta-galactosidase-carboxypeptidase complex or NGC-complex) and that these species undergo slow conversion into one another through dissociation and association of protomeric components. Each species was sufficiently stable for the determination of their hydrodynamic properties by gel-filtration h.p.l.c. and sedimentation velocity. The largest species had an apparent sedimentation coefficient S20.w, of 18.8 S and a Stokes' radius of 8.5 nm, giving a molecular mass of 679 kDa and a fractional ratio, f/f min, of 1.47. The latter value indicates that the macromolecule is asymmetric or highly hydrated. This large species is composed of four types of polypeptide chains of molecular mass 66 kDa (neuraminidase), 63 kDa (beta-galactosidase), 32 kDa and 20 kDa (carboxypeptidase heterodimer). The 32 kDa and 20 kDa protomers are linked together by a disulphide bridge. Glycopeptidase F digestion of the NGC-complex transformed the diffuse 66-63 kDa band on the SDS gel into two close but sharp bands at 58 and 56 kDa. The two smaller species which were separated on the h.p.l.c. column correspond to tetrameric and dimeric forms of the 66-63 kDa protomers and express exclusively beta-galactosidase activity. Treatment of the NGC-complex with increasing concentrations of guanidinium hydrochloride up to 1.5 M also resulted in dissociation of the complex into the same smaller species mentioned above plus two protomers of molecular mass around 60 and 50 kDa. A model of the largest molecular species as a hexamer of the 66-63 kDa protomers associated to five carboxypeptidase heterodimers (32 kDa and 20 kDa) is proposed

Carboxypeptidases↗
PubMed1973

Induction of lymphocyte transformation by sequential treatment with neuraminidase and galactose oxidase.

Treatment of mouse-spleen cells with galactose oxidase (EC 1.1.3.9) after incubation with neuraminidase (EC 3.2.1.18) induced extensive blastogenesis. Treatment of the cells with galactose oxidase before incubation with neuraminidase had very little stimulatory effect. Either of these enzymes alone had practically no effect on the cells. The lymphocyte transformation induced by galactose oxidase in neuraminidase-treated cells was decreased upon reacting the cells with borohydride or hydroxylamine, whereas treatment with these compounds did not affect transformation of cells by concanavalin A. It is suggested that galactosyl residues exposed by the action of neuraminidase on the cell membrane are oxidized by galactose oxidase, and the aldehyde moiety thus formed is involved in the induction of blastogenesis.

Alcohol Oxidoreductases↗
PubMed1973

Transformation of neuraminidase-treated lymphocytes by soybean agglutinin.

Transformation of mouse-spleen lymphocytes in the presence of soybean agglutinin is markedly enhanced after their treatment with neuraminidase (EC 3.2.1.18). Incubation of the cells with the enzyme also facilitates their agglutination by the lectin. The soybean agglutinin-induced agglutination and transformation is inhibited specifically by N-acetyl-D-galactosamine. New specific binding sites for soybean agglutinin were shown to appear after neuraminidase treatment. It is postulated that the transformation of neuraminidase-treated mouse-spleen lymphocytes induced by soybean agglutinin is caused by the binding of the lectin to galactosyl residues exposed by the action of neuraminidase on the cell membrane.

Animals↗
PubMed1978

Membrane-bound neuraminidase from calf brain: regulation of oligosialoganglioside degradation by membrane fluidity and membrane components.

The degradation of lipophilic ganglioside GD1a and hydrophilic sialyllactitol by membrane-bound neuraminidase (EC 3.2.1.18) from calf brain has been studied at substrate concentrations of 0.1 mM. Ganglioside GD1a taken up by cell membranes is hydrolyzed faster membrane-bound neuraminidase than are water-soluble substrates of the enzyme, sialyllactitol and des-GD1a. Availability and enzymic breakdown of the disialoganglioside are enhanced by general anesthetics such as N2O or halothane whereas the degradation of the hydrophilic substrate silayllactitol is not affected or even is decreased by these agents. General anesthetics lower the microviscosity of membranes as indicated by studies of fluorescence depolarization with the indicator 1,6-diphenylhexatriene. Increased fluidity can result in higher lateral diffusion of ganglioside GD1a, thus increasing its chances of presentation to, and interaction with, membrane-bound neuraminidase. Lipophilic derivatives of the disialoganglioside, gangliosides GM1 and GM2 and gangliotriaosylceramide GA2, are strong inhibitors of the ganglioside degradation whereas water-soluble derivatives des-GM1, des-GM2, N-acetylneuraminic acid, and sialyllactose are not. A model is presented that suggests that the activity of membrane-bound neuraminidase on gangliosides of brain membranes is regulated by the viscosity of these membranes and their monosialoganglioside content.

Anesthesia, General↗
PubMed2003

Pathogenesis and pathology of blackleg in ruminants: the role of toxins and neuraminidase. A short review.

There is no consensus on the pathogenesis of blackleg infection that occurs in ruminants, but toxins and neuraminidase produced by Clostridium chauvoei are believed to play a significant role in the pathogenesis of the disease. This paper provides an update on the role of toxins and neuraminidase in the pathogenesis and pathology of the disease. The use of neuraminidase inhibitors to manage clinical blackleg infections is therefore an alternative therapeutic protocol that should be thoroughly investigated. It is suggested that in vivo clinical trials should be carried out to determine the mechanism of action and clinical efficacy of neuraminidase inhibitors.

Animals↗
PubMed1988

Neuraminidase-treated macrophages stimulate allogenic CD8+ T cells in the presence of exogenous interleukin 2.

Prior work has shown that purified, resident, and inflammatory peritoneal macrophages are weak stimulators of the allogeneic MLR. We have identified conditions whereby thioglycollate-elicited macrophages become stimulatory, but primarily for the CD8+ T cell subset. The conditions were to treat the macrophages with neuraminidase and to supplement the MLR with rIL-2. These treatments together led to proliferative and cytotoxic responses by isolated CD8+ but not CD4+ T cells. Likewise when MHC-congenic strains were evaluated, an MLR was observed across isolated class I but not class II MHC barriers. Pretreatment of the macrophages with IFN-gamma further enhanced expression of class I MHC products and stimulatory activity, but did not seem essential. While these treatments did not render macrophages stimulatory for an MLR in purified CD4+ cells, blastogenesis of CD4+ cells was observed when the MLR involved bulk T cells. Small allogeneic B lymphocytes behaved similarly to macrophages, in the pretreatment with neuraminidase and supplementation with rIL-2 rendered B cells stimulatory for allogeneic, enriched, CD8+, but not CD4+, T cells. Spleen adherent cells, which are mixtures of macrophages and dendritic cells, stimulated both CD4+ and CD8+ T cells, and neither neuraminidase nor exogenous IL-2 was required. We think that these data suggest that most macrophages and small B cells lack three important functions of dendritic cells: a T cell-binding function that can be remedied by neuraminidase treatment, a T cell growth factor-inducing function that can be bypassed with exogenous IL-2, and an IL-2 responsiveness function that is required by CD4+ lymphocytes.

Animals↗
PubMed1986

Genetic analysis of liver neuraminidase isozymes in Rattus norvegicus: independent control of NEU-1 and NEU-2 phenotypes.

Two recently identified isozymes of neuraminidase in rat liver were examined for transmission patterns and linkage relationships, and for variation among inbred strains. The isozymes, designated neuraminidase-1 (NEU-1) and neuraminidase-2 (NEU-2), exhibited no electrophoretic mobility variants among the 22 inbred strains examined, but did possess striking interstrain variation in activity phenotypes on electrophoretic gels. The results of a backcross analysis involving the KGH and ACP strains revealed that NEU-1 and NEU-2 phenotypes are independently controlled, each by a single autosomal locus with additively acting alleles. The two loci are unlinked to one another, but the gene controlling NEU-1 is tightly linked to RT1, the rat major histocompatibility complex. This gene is almost certainly identical to Neu-1, a gene identified previously through its effect on "total" activity levels of liver neuraminidase as determined by fluorometric assay of tissue homogenates. NEU-2 and the gene controlling its phenotype were not detected by the fluorometric technique. We designate the genes controlling the NEU-1 and NEU-2 phenotypes as Neu-1 and Neu-2, respectively. Data from this and other studies place Neu-1 between Glo-1 and dw-3. The location of Neu-2 is unknown.

Animals↗
PubMed2000

Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis.

Lysosomal neuraminidase is the key enzyme for the intralysosomal catabolism of sialylated glycoconjugates and is deficient in two neurodegenerative lysosomal disorders, sialidosis and galactosialidosis. Here we report the identification of eight novel mutations in the neuraminidase gene of 11 sialidosis patients with various degrees of disease penetrance. Comparison of the primary structure of human neuraminidase with the primary and tertiary structures of bacterial sialidases indicated that most of the single amino acid substitutions occurred in functional motifs or conserved residues. On the basis of the subcellular distribution and residual catalytic activity of the mutant neuraminidases we assigned the mutant proteins to three groups: (i) catalytically inactive and not lysosomal; (ii) catalytically inactive, but localized in lysosome; and (iii) catalytically active and lysosomal. In general, there was a close correlation between the residual activity of the mutant enzymes and the clinical severity of disease. Patients with the severe infantile type II disease had mutations from group I, whereas patients with a mild form of type I disease had at least one mutation from group III. Mutations from the second group were mainly found in juvenile type II patients with intermediate clinical severity. Overall, our findings explain the clinical heterogeneity observed in sialidosis and may help in the assignment of existing or new allelic combinations to specific phenotypes.

Adolescent↗
PubMed1977

Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.

Groups of schoolchildren were immunized with an inactivated recombinant influenza virus vaccine specific for the neuraminidase antigen of Port Chalmers influenza A virus (Heq1N2Ch), a conventional biphasic Port Chalmers strain of influenza virus vaccine (H3ChN2Ch), or a placebo. Immunization with either virus vaccine was found to be safe and had no major adverse effects. Immunization with the Heq1N2Ch vaccine resulted in no specific hemagglutination-inhibiting antibody response to H3Ch antigen, although a specific neuraminidase antibody response to N2Ch antigen was observed in greater than 90% of the vaccinees. A subsequent natural outbreak of influenza virus resulted in serologically proven infection with H3Ch virus in 26% of vaccinees receiving H3ChN2Ch virus vaccine, 47% of those receiving Heq1N2Ch virus vaccine, and 44% of those receiving a placebo. However, the protective efficacy against illness was 74.3% for the H3ChN2Ch vaccine and only 51.4% for the Heq1N2Ch vaccine. Regardless of the type of vaccine employed, vaccinees with serologic evidence of infection and clinical illness were found to have very low titers of hemagglutination-inhibiting and neuraminidase antibody. However, vaccinees with serologically proved infection but without clinical illness were found to have titers of antibody to neuraminidase before infection that were four- to eightfold higher than titers in vaccinees who were infected and who had clinical illness.

Antibody Formation↗
PubMed1982

Reevaluation of the effect of follicle-stimulating hormone on the steroidogenic capacity of the testis: the effects of neuraminidase-treated FSH preparations.

The ability of FSH treatment to increase the amount of androgen produced by the testis in response to maximum LH stimulation may be an effect of the LH contamination of the FSH preparations. To examine this question, 3 FSH preparations of different potencies and degrees of LH contamination or their neuraminidase-treated derivatives were administered to hypophysectomized immature rats for 5 days. The capacity of the testes to produce androgens in vitro was assessed at the end of the treatment period. Neuraminidase treatment reduces the in vivo activity of ovine and bovine FSH but does not alter the activity of ovine or bovine LH. Neuraminidase treatment of one FSH preparation (NH-bFSH-B1) did not reduce the ability of this FSH preparation to increase the response of the testis to LH stimulation in vitro. This suggests that the considerable LH contamination of the NIH-bFSH-B1 may be responsible for its effect. However, neuraminidase treatment of 2 more highly purified FSH preparations (bFSH-199C and NIH-oFSH-S13) abolished or greatly reduced the ability of these preparations to increase testicular weight and the response to LH in vitro. It is concluded that the ability of highly-purified FSH preparations to increase the amount of androgen produced by the testis is due to FSH activity and not the contaminating LH.

Androgens↗